Haggett K D, Graham L D, Milner S J, Whittaker R G
Sydney Laboratory, CSIRO Division of Biomolecular Engineering, North Ryde, NSW, Australia.
Arch Biochem Biophys. 1994 Oct;314(1):132-41. doi: 10.1006/abbi.1994.1421.
A procedure is described for purifying alpha-lytic protease and its mutants from culture supernatants of recombinant Escherichia coli. The method affords substantial amounts (approx. 80 mg) of homogeneous enzyme. We compared the cleavage preferences of wild-type alpha-lytic protease and of mutants containing the substitutions Ala190 ("parent"), Ala190/Val192/His213/Met218 (mutant 1), Ala190/His213/Leu218 (mutant 9), and Ala190/Thr213/Leu218 (mutant 55), and for each enzyme we found broad agreement between the results obtained with synthetic ester and amide substrates. Kinetic constants were determined for the purified enzymes using selected tetrapeptide p-nitroanilide substrates. Mutant 55 had broad specificity and high activity. In terms of kcat/Km it cleaved at Met and Phe residues two to three times as effectively as the Ala190 enzyme and cleaved at Ala 7 times more effectively than the wild-type protease. The Ala190/His213 enzymes showed a preference for cleavage at His and Met residues. Not only were their kcat values for cleavage at His increased (in relation to the Ala190 enzyme) by an order of magnitude, but they also exhibited large decreases in kcat/Km for cleavage at other residues; for example, the value for cleavage at Phe was 400- to 600-fold lower. Mutant 9 cleaved a recombinant IGF-II fusion protein at a unique His residue and also at a nearby Asn residue.
描述了一种从重组大肠杆菌培养上清液中纯化α-裂解蛋白酶及其突变体的方法。该方法可提供大量(约80毫克)的纯酶。我们比较了野生型α-裂解蛋白酶以及含有Ala190(“亲本”)、Ala190/Val192/His213/Met218(突变体1)、Ala190/His213/Leu218(突变体9)和Ala190/Thr213/Leu218(突变体55)替换的突变体的切割偏好,对于每种酶,我们发现使用合成酯和酰胺底物获得的结果之间具有广泛的一致性。使用选定的四肽对硝基苯胺底物测定了纯化酶的动力学常数。突变体55具有广泛的特异性和高活性。就kcat/Km而言,它在Met和Phe残基处的切割效率是Ala190酶的两到三倍,在Ala处的切割效率比野生型蛋白酶高7倍。Ala190/His213酶表现出对His和Met残基切割的偏好。不仅它们在His处切割的kcat值(相对于Ala190酶)增加了一个数量级,而且它们在其他残基处切割的kcat/Km也大幅降低;例如,在Phe处切割的值低400至600倍。突变体9在一个独特的His残基以及附近的Asn残基处切割重组IGF-II融合蛋白。